Protinex Ultra5%+10%

Protinex Ultra is a combination nutritional and fluid/electrolyte replacement solution used to provide caloric (dextrose), protein-building (amino acid), and electrolyte support when normal oral or enteral intake is inadequate, not possible, or contraindicated.

Established uses

• Parenteral nutrition support (adjunct/total): Protinex Ultra is used intravenously, under medical supervision, to supply calories, nitrogen (amino acids), and electrolytes in patients who cannot meet nutritional requirements orally or enterally (e.g., post-operative patients, critically ill patients, patients with prolonged gastrointestinal dysfunction).
• Fluid and electrolyte replacement: Used to correct or prevent dehydration and electrolyte deficits accompanying inadequate intake, increased losses, or metabolic stress.

Guideline-supported / adjunct uses

• As an adjunct to enteral feeding when enteral intake alone is insufficient to meet caloric/protein/electrolyte needs (partial parenteral nutrition).
• Peri-operative and critical-care nutritional support as part of a broader nutrition care plan directed by a physician or clinical nutrition team.

Note: Protinex Ultra is available in different formulations (oral/enteral nutritional-rehydration solutions and intravenous parenteral nutrition solutions). The exact indication, concentration, and route depend on the specific product formulation prescribed; oral/enteral use and intravenous (parenteral) use have very different administration routes, monitoring requirements, and risk profiles and must not be interchanged.

Amino Acid + Dextrose+ Electrolytes is a combination product typically containing three components:

• Amino acids — a mixture of essential and non-essential crystalline amino acids providing a nitrogen source for protein synthesis.
• Dextrose (glucose) — a carbohydrate source providing calories/energy, available in varying concentrations depending on the formulation.
• Electrolytes — commonly sodium, potassium, chloride, calcium, magnesium, phosphate, and/or acetate, added to support fluid and electrolyte balance.

Exact concentrations and electrolyte content vary by brand/formulation of Amino Acid + Dextrose+ Electrolytes; the prescribing physician selects the specific formulation based on the patient's nutritional and metabolic needs.

Protinex Ultra is a combination nutritional/rehydration solution that brings together amino acids (for protein/nitrogen support), dextrose (for caloric/energy support), and electrolytes (for fluid and electrolyte balance) in a single formulation. It is used, depending on the specific product and route, to support nutrition and hydration in patients who are unable to meet their needs through normal food and fluid intake.

Protinex Ultra formulations intended for intravenous (parenteral) use are administered only under medical supervision, typically in a hospital or clinical setting, with monitoring of blood glucose, electrolytes, and fluid status. Oral/enteral formulations of Protinex Ultra are used for nutritional supplementation or rehydration under a physician's or qualified healthcare provider's direction.

Protinex Ultra belongs to the therapeutic class of Parenteral/Enteral Nutrition Solutions and Fluid & Electrolyte Replacement Preparations.

Amino Acid + Dextrose+ Electrolytes combines three pharmacologically distinct components that act together to support nutrition and fluid/electrolyte balance:

• Amino acids supply the nitrogen and essential/non-essential amino acids required for protein synthesis, tissue repair, and maintenance of lean body mass, particularly important during catabolic states (surgery, critical illness, malnutrition).
• Dextrose is metabolized to provide calories/energy, sparing protein from being used as an energy source and supporting glucose-dependent tissues (e.g., central nervous system).
• Electrolytes (such as sodium, potassium, chloride, calcium, magnesium, and phosphate) help maintain osmotic balance, acid-base status, neuromuscular function, and cellular metabolic processes.

Together, these components in Amino Acid + Dextrose+ Electrolytes address caloric, protein, and electrolyte deficits when oral/enteral intake is insufficient or not possible.

Intravenous formulations of Protinex Ultra are given as a slow, controlled infusion via a peripheral or central venous line (depending on the osmolarity of the specific formulation), using appropriate infusion equipment (e.g., infusion pump) to control the rate. Aseptic technique must be used throughout preparation and administration. Do not co-infuse with blood products through the same line, and check formulation-specific compatibility before adding any other medication to the infusion.

Oral/enteral formulations of Protinex Ultra are taken by mouth or via feeding tube exactly as directed by the prescribing physician or product labeling.

Protinex Ultra should be used cautiously with the following, due to well-recognized clinically significant interactions:

• Insulin and other glucose-lowering agents: the dextrose component of Protinex Ultra can alter blood glucose control, requiring dose adjustment of insulin/oral hypoglycemic agents and closer glucose monitoring.
• Corticosteroids and other hyperglycemia-inducing drugs: may add to the hyperglycemic effect of the dextrose in Protinex Ultra, increasing insulin requirements.
• Potassium-sparing diuretics, ACE inhibitors/ARBs, and other drugs affecting potassium: may interact with the potassium content of Protinex Ultra, increasing the risk of hyperkalemia; electrolyte monitoring is advised.
• Other intravenous additives/medications: calcium- and phosphate-containing components of Protinex Ultra can form precipitates if mixed with incompatible drugs or solutions in the same line; formulation-specific compatibility must be verified before co-administration.

Side effects of Protinex Ultra depend on the formulation, route, dose, and rate of administration. Reported effects include:

• Metabolic: hyperglycemia, hypoglycemia (on abrupt discontinuation of an infusion), electrolyte imbalances (e.g., hyperkalemia/hypokalemia, hypernatremia/hyponatremia), fluid overload.
• Infusion-related (IV use): infusion-site pain, redness, swelling, phlebitis, or thrombosis at the injection site.
• Hypersensitivity: rash, itching, or, rarely, more serious allergic reactions.
• Gastrointestinal (oral/enteral use): nausea, bloating, or diarrhea, particularly if taken too quickly or in excessive amounts.

Patients should seek prompt medical attention for signs of severe allergic reaction, significant swelling, breathing difficulty, or symptoms of marked hyperglycemia or fluid overload while receiving Protinex Ultra.

Protinex Ultra should be used in pregnancy and lactation only if clearly needed, with the formulation, dose, and rate individualized by the treating physician after weighing the potential benefit of nutritional/fluid support against any potential risk. Nutritional and fluid/electrolyte support with Protinex Ultra may be required in pregnancy or during breastfeeding when oral intake is inadequate, but should always be supervised by a physician experienced in maternal-fetal or lactation care, with appropriate monitoring of glucose and electrolytes. Consult a physician before use in pregnancy or while breastfeeding.

Protinex Ultra, particularly intravenous (parenteral) formulations, must be administered under medical supervision with monitoring of blood glucose, serum electrolytes, and fluid balance, because of the risk of hyperglycemia, electrolyte imbalance, or fluid overload if not properly monitored.

• Diabetes mellitus: the dextrose content of Protinex Ultra requires close blood glucose monitoring and possible insulin dose adjustment.
• Renal or cardiac impairment: increased risk of fluid overload and electrolyte disturbance; use with caution and closer monitoring.
• Route distinction: oral/enteral nutritional-rehydration formulations of Protinex Ultra and intravenous parenteral-nutrition formulations of Protinex Ultra have very different administration routes, monitoring requirements, and risk profiles and must not be substituted for one another.
• Infusion site: monitor intravenous infusion sites regularly for signs of infiltration, phlebitis, or infection.
• See Contraindications for absolute restrictions on use.

Overdose or excessively rapid administration of Protinex Ultra can result in hyperglycemia, hyperosmolar state, fluid overload, or electrolyte disturbances (e.g., hyperkalemia, hypernatremia), which may present as confusion, weakness, irregular heartbeat, swelling, or breathing difficulty. If overdose is suspected, the infusion/intake should be stopped and immediate medical attention should be sought, or emergency services/poison control contacted; management should be carried out by qualified healthcare professionals with appropriate monitoring and supportive care. Do not attempt specific home treatment for a suspected overdose of Protinex Ultra.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze intravenous solutions. Keep out of reach of children. Discard any unused portion of an opened container; do not use if the solution is discolored, cloudy, or the container is damaged.

Renal impairment: use Protinex Ultra with caution; dose, fluid volume, and electrolyte content should be adjusted under close monitoring, as impaired renal function limits the ability to excrete fluid and electrolyte loads.

Hepatic impairment: use Protinex Ultra with caution; amino acid and fluid load should be adjusted based on clinical status and monitored closely.

Elderly: may have reduced renal or cardiac reserve; use Protinex Ultra with caution and closer monitoring of fluid and electrolyte status.

Diabetes mellitus: requires close blood glucose monitoring and possible adjustment of glucose-lowering therapy; see Interactions and Precautions.

The duration of treatment with Protinex Ultra is determined by the treating physician based on the underlying clinical indication, the patient's nutritional and fluid/electrolyte status, and the ability to resume adequate oral or enteral intake. Parenteral nutrition support with Protinex Ultra is generally continued only for as long as normal nutrition cannot be adequately achieved by mouth or enteral tube feeding, with periodic reassessment.

Certain Protinex Ultra formulations (e.g., multi-chamber parenteral nutrition bags) require activation/admixture immediately before use: the internal seals between the amino acid, dextrose, and electrolyte compartments must be broken and the contents thoroughly mixed under aseptic technique, following the specific product's instructions, immediately prior to infusion. Any additive medications or trace elements/vitamins should only be added if formulation-specific compatibility has been confirmed. Once mixed or additives are added, use within the time frame specified by the product labeling and discard any unused solution.

Parenteral/enteral nutrition solutions; carbohydrate (dextrose) caloric agents; crystalline amino acid solutions; electrolyte and fluid replacement solutions.

Amino Acid + Dextrose+ Electrolytes acts through the combined, complementary effects of its three components: amino acids provide substrate for protein synthesis and nitrogen balance; dextrose is metabolized to yield energy (ATP) and spares protein from being catabolized for calories; and electrolytes maintain osmotic pressure, membrane potential, acid-base balance, and support normal cellular and neuromuscular function. Together, Amino Acid + Dextrose+ Electrolytes helps correct or prevent deficits in calories, protein, and electrolytes when normal nutritional intake is inadequate.

Protinex Ultra may be used in pediatric patients, including infants, for parenteral or enteral nutritional support when oral intake is inadequate, but only under the direction of a pediatrician or pediatric nutrition specialist. Dosing is individualized on a weight (mg/kg or mL/kg) basis according to the child's age, weight, caloric/protein/fluid requirements, and clinical condition. Safety and efficacy of specific Protinex Ultra formulations in neonates and very young infants should follow the specific product's labeling, as concentrations and electrolyte content suitable for adults may not be appropriate for neonates. Close monitoring of blood glucose, electrolytes, growth, and fluid balance is required in pediatric use.